Novelix Pharma.

{
  "main_header": {
    "sid": 200695,
    "name": "Novelix Pharma.",
    "stock_name": "Novelix Pharma.",
    "full_name": "Novelix Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/novelix-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "62.98",
    "chg": 0.4,
    "chgp": "0.64%",
    "dir": 1,
    "prev_price": "62.58",
    "mcapval": "110.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 536565,
    "symbol": "",
    "ind_name": "Retailing",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE314I01036",
    "curr_date": "Feb 12",
    "curr_time": "",
    "bse_nse_vol": "68 ",
    "exc_status": "Active",
    "traded_date": "Feb 12, 2026",
    "traded_date_str": "2026 02 12",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/novelix-pharma-200695-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "When is the next results date for Novelix Pharmaceuticals Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-novelix-pharmaceuticals-ltd-3831936",
        "imagepath": "",
        "date": "2026-02-10 23:18:40",
        "description": "The next results date for Novelix Pharmaceuticals Ltd is scheduled for 12 February 2026...."
      },
      {
        "title": "Novelix Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/novelix-pharmaceuticals-ltd-is-rated-sell-3830393",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/NovelixPharmace_mojoScore_3830393.png",
        "date": "2026-02-10 10:11:11",
        "description": "Novelix Pharmaceuticals Ltd is rated Sell by MarketsMOJO, with this rating last updated on 05 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 February 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Novelix Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/novelix-pharmaceuticals-ltd-is-rated-sell-3811007",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/NovelixPharmace_mojoScore_3811007.png",
        "date": "2026-01-30 10:11:27",
        "description": "Novelix Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO. This rating was last updated on 05 Jan 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 30 January 2026, providing investors with the latest perspective on the company’s position."
      },
      {
        "title": "Novelix Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/novelix-pharmaceuticals-ltd-is-rated-sell-3793952",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/NovelixPharmace_mojoScore_3793952.png",
        "date": "2026-01-19 10:10:46",
        "description": "Novelix Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Novelix Pharmaceuticals Downgraded to Sell Amid Mixed Technicals and Valuation Concerns",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/novelix-pharmaceuticals-downgraded-to-sell-amid-mixed-technicals-and-valuation-concerns-3782562",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/NovelixPharmace_mojoScore_3782562.png",
        "date": "2026-01-06 08:20:00",
        "description": "Novelix Pharmaceuticals Ltd has seen its investment rating downgraded from Hold to Sell as of 5 January 2026, reflecting a combination of deteriorating technical indicators, expensive valuation metrics, and weak long-term fundamentals despite recent positive quarterly financial results."
      },
      {
        "title": "Novelix Pharmaceuticals Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/novelix-pharmaceuticals-ltd-is-rated-hold-3769566",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NovelixPharmace_mojoScore_3769566.png",
        "date": "2025-12-25 15:13:16",
        "description": "Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 08 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "Novelix Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-faces-severe-selling-pressure-hits-lower-circuit-amid-market-turmoil-3748017",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NovelixPharmace_only_sellers_3748017.png",
        "date": "2025-12-05 09:30:20",
        "description": "Novelix Pharmaceuticals has encountered significant selling pressure, with the stock registering a sharp decline of 4.99% today and exhibiting a distinct absence of buyers. This marks the third consecutive day of losses, reflecting a sustained period of distress selling that has weighed heavily on investor sentiment."
      },
      {
        "title": "Novelix Pharmaceuticals: Analytical Review Highlights Key Shifts in Market Assessment",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/novelix-pharmaceuticals-downgraded-to-sell-amid-mixed-technicals-and-valuation-concerns-3747716",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NovelixPharmace_mojoScore_3747716.png",
        "date": "2025-12-05 08:06:04",
        "description": "Novelix Pharmaceuticals has undergone a notable revision in its market evaluation, reflecting shifts across multiple analytical parameters including quality, valuation, financial trends, and technical indicators. This article examines the underlying factors influencing these changes and their implications for investors within the retailing sector."
      },
      {
        "title": "How has been the historical performance of Novelix Pharma.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-novelix-pharma-3747097",
        "imagepath": "",
        "date": "2025-12-04 22:46:23",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Operating Performance Trends</strong></p>\n<p>Net sales for Novelix Pharma. peaked around the fiscal year ending March 2018 at approximately ₹10.50 crores but have since shown a gradual decline, falling to ₹8.61 crores by March 2022. The total operating income mirrored this trend, with a notable drop from ₹10.50 crores in 2018 to ₹8.61 crores in 2022. The company’s cost structure reveals a significant reliance on the purchase of finished goods, which constituted the largest share of expenditure, increasing from ₹4.12 crores in 2016 to ₹8.26 crores in 2022. Raw material costs remained relatively low but fluctuated, while employee costs showed a modest increase over the years.</p>\n<p>Operating profit margins have deteriorated sharply, with the company reporting negative margins cons..."
      }
    ],
    "total": 102,
    "sid": "200695",
    "stock_news_url": "https://www.marketsmojo.com/news/novelix-pharmaceuticals-200695"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Prior Intimation Of Board Meeting To Be Held On Thursday 12Th February 2026 Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015",
      "datetime": "09-Feb-2026",
      "details": "Novelix Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 inter alia to consider and approve 1. To Consider and Approve the unaudited standalone financial results for the quarter ended 31st December 2025 along with Limited Review Report of the auditors; 2. To Consider and approve the allotment of equity shares issued through preferential allotment basis. 3. Any other matter with the permission of chair.",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "21-Jan-2026",
      "details": "Submission of Certificate Under Reg. 74 (5) of SEBI (DP) Regulations 2018.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Allotment",
      "datetime": "20-Jan-2026",
      "details": "Submission of Intimation of allotment.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "(12 Feb 2026)"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Novelix Pharmaceuticals Ltd has declared <strong>3%</strong> dividend, ex-date: 16 Aug 12",
          "dt": "2012-08-16",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Novelix Pharmaceuticals Ltd has announced <strong>10:1</strong> stock split, ex-date: 04 Oct 10",
          "dt": "2010-10-04",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

When is the next results date for Novelix Pharmaceuticals Ltd?

2026-02-10 23:18:40

The next results date for Novelix Pharmaceuticals Ltd is scheduled for 12 February 2026....

Read full news article

Novelix Pharmaceuticals Ltd is Rated Sell

2026-02-10 10:11:11

Novelix Pharmaceuticals Ltd is rated Sell by MarketsMOJO, with this rating last updated on 05 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 February 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Novelix Pharmaceuticals Ltd is Rated Sell

2026-01-30 10:11:27

Novelix Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO. This rating was last updated on 05 Jan 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 30 January 2026, providing investors with the latest perspective on the company’s position.

Read full news article

Novelix Pharmaceuticals Ltd is Rated Sell

2026-01-19 10:10:46

Novelix Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Novelix Pharmaceuticals Downgraded to Sell Amid Mixed Technicals and Valuation Concerns

2026-01-06 08:20:00

Novelix Pharmaceuticals Ltd has seen its investment rating downgraded from Hold to Sell as of 5 January 2026, reflecting a combination of deteriorating technical indicators, expensive valuation metrics, and weak long-term fundamentals despite recent positive quarterly financial results.

Read full news article

Novelix Pharmaceuticals Ltd is Rated Hold

2025-12-25 15:13:16

Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 08 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with the latest insights into its performance and outlook.

Read full news article

Novelix Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses

2025-12-05 09:30:20

Novelix Pharmaceuticals has encountered significant selling pressure, with the stock registering a sharp decline of 4.99% today and exhibiting a distinct absence of buyers. This marks the third consecutive day of losses, reflecting a sustained period of distress selling that has weighed heavily on investor sentiment.

Read full news article

Novelix Pharmaceuticals: Analytical Review Highlights Key Shifts in Market Assessment

2025-12-05 08:06:04

Novelix Pharmaceuticals has undergone a notable revision in its market evaluation, reflecting shifts across multiple analytical parameters including quality, valuation, financial trends, and technical indicators. This article examines the underlying factors influencing these changes and their implications for investors within the retailing sector.

Read full news article

How has been the historical performance of Novelix Pharma.?

2025-12-04 22:46:23

Revenue and Operating Performance Trends

Net sales for Novelix Pharma. peaked around the fiscal year ending March 2018 at approximately ₹10.50 crores but have since shown a gradual decline, falling to ₹8.61 crores by March 2022. The total operating income mirrored this trend, with a notable drop from ₹10.50 crores in 2018 to ₹8.61 crores in 2022. The company’s cost structure reveals a significant reliance on the purchase of finished goods, which constituted the largest share of expenditure, increasing from ₹4.12 crores in 2016 to ₹8.26 crores in 2022. Raw material costs remained relatively low but fluctuated, while employee costs showed a modest increase over the years.

Operating profit margins have deteriorated sharply, with the company reporting negative margins cons...

Read full news article

View All News